Zidovudine/lamivudine ( DrugBank: Zidovudine, Lamivudine )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 26 | HTLV-1-associated myelopathy | 1 |
26. HTLV-1-associated myelopathy
Clinical trials : 28 / Drugs : 48 - (DrugBank : 28) / Drug target genes : 38 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00272480 (ClinicalTrials.gov) | November 8, 1999 | 4/1/2006 | Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial | Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial | HTLV-I-associated Myelopathy | Drug: Zidovudine/lamivudine;Drug: Placebos | Imperial College London | NULL | Completed | 16 Years | 75 Years | All | 16 | Phase 2/Phase 3 | United Kingdom |